# Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment

> **NCT00453310** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 10 (actual)

## Conditions studied

- Extragonadal Germ Cell Tumor
- Ovarian Cancer
- Teratoma
- Testicular Germ Cell Tumor

## Interventions

- **DRUG:** sunitinib malate

## Key facts

- **NCT ID:** NCT00453310
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2015-10-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00453310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00453310, "Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00453310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*